AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05780593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclined Board Standing
Description: The patients in Group B will be asked to stick to their medications if advised and stand on the inclined board for 01 minute. Inclined boards will be provided to all patients and will be advised to follow the inclined standing for 01 minute for three times a day at home for two weeks. After two weeks at the completion of intervention, they will be assessed through self-reporting questionnaires of the study.
Study NCT04818749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline (placebo) will be administered intravenously before block performance and after the induction of general anaesthesia.
Study NCT04818749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 12 mg
Description: Dexamethasone 12 mg will be administered intravenously before block performance and saline (placebo) will be administered intravenously after the induction of general anaesthesia.
Study NCT04818749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg + dexmedetomidine 1 mcg/kg
Description: Dexamethasone 12 mg will be administered intravenously before block performance and dexmedetomidine 1 mcg/kg will be administered intravenously after the induction of general anaesthesia.
Study NCT06015399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation of closed insufflation technique during segmentectomy
Description: After the identification the targeted segmental bronchus during the operation,ligating the proximal end of the targeted bronchus. Put the vessel separation forceps in the distal bronchial space to avoid the accidental damage of the vessels. Use a 50ml syringe to inject air into the distal bronchus (about 100ml is expected) until the intersegmental plane is satisfactory. Divide the target bronchus using the cutting and closing device.
Study NCT06015399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implementation of dilatation and collapse technique during segmentectomy
Description: Divide the target bronchus using the cutting and closing device. Ask the anesthesiologist to inflate the lung completely from pure oxygen to the affected side and then change to single lung ventilation. Wait for the intersegmental plane to appear(usually about 15 minutes).
Study NCT05574894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: Growth hormone is supplemented during the ovarian stimulation till the day of trigger
Study NCT05574894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: GnRH antagonist protocol for ovarian stimulation
Study NCT05518253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study NCT05518253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: Administration method: intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study NCT05125107 — intervention group
Intervention type: DEVICE
Intervention: Quantitative Flow Ratio derived PPG and dQFR/ds
Description: From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2~Physiologic local severity of coronary atherosclerosis was assessed by instantaneous QFR gradient per unit length (dQFR/ds)
Study NCT06180759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of DMT
Description: A dose rate of 1.2 mg/min will be administered
Study NCT06180759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous infusion of ketamine
Description: A dose rate of 1.0 mg/min will be administered
Study NCT06180759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous infusion of placebo
Description: A Placebo (saline infusion) will be administered.
Study NCT06079866 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mask A (Oran Park Mask) then Mask B (Evora Mask)
Description: Mask A (Oran Park Mask) for 7 days followed by Mask B (Evora Mask) for 7 days
Study NCT06079866 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mask B (Evora Mask) then Mask A (Oran Park Mask)
Description: Mask B (Evora Mask) for 7 days followed by Mask A (Oran Park Mask) for 7 days.
Study NCT05017714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant cytokine gene derived protein injection
Description: Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care.~Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care.
Study NCT05017714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant cytokine gene derived protein injection
Description: Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care.~Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care.
Study NCT05574894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist protocol for ovarian stimulation
Study NCT04669717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days
Description: Non-surgical periodontal therapy and radnomly administration of the antibiotics
Study NCT04669717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 3 days
Description: Non-surgical periodontal therapy and radnomly administration of the antibiotics
Study NCT04669717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1/d 500 mg Azithromycine Pfizer for 3 days
Description: Non-surgical periodontal therapy and radnomly administration of the antibiotics
Study NCT06392204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAD/CAM patient specfifc fracture reduction/plate guide and customized 3D grid plate
Description: Mandibular angle fracture reduction and fixation using digitally designed and fabricated patient specific fracture reduction/plate positioning guide and customized 3D grid plate
Study NCT06392204 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Champy's techqniue
Description: Mandibular angle fracture reduction and fixation using a single superior border 2.0 miniplate
Study NCT05060432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS-448
Description: Anti-TIGIT monoclonal antibody
Study NCT05060432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Anti-PD-1 monoclonal antibody
Study NCT05060432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inupadenant
Description: A2A receptor antagonist
Study NCT05060432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Anti-PD-1 monoclonal antibody
Study NCT05419570 — intervention group
Intervention type: OTHER
Intervention: Fluid Loading
Description: Hemodynamic and ventilatory parameters will be recorded at five time points (T1 - T5). After baseline meausrements (T1), additional 5 cmH2O PEEP will be applied to patients for 30 seconds (short time low peep challenge, SLPC). Prior to PEEP lowering T2 measurement will be performed. T3 measurement will be performed one minute after PEEP is decreased to its initial value and will be recorded as the second baseline. Thereafter, 100 ml isotonic saline will be infused over one minute (MFC). T4 measurement will be performed one minute after MFC is completed,. Lastly, T5 measurement will be performed three minutes after additional 400 ml of isotonic saline is infused within 10 minutes to complete 500 ml of fluid loading.
Study NCT04907071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)
Description: The investigational 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) is an over the wire catheter-based ultrasound with an 8.2-French profile at the transducer end and 7.0-French shaft diameter. This is run through a 9-French place under surface ultrasound guidance in the common femoral artery. The working length of this catheter is 90 cm, with the ability to imaging a diameter up to 60 mm.7
Study NCT05378412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3Cs
Description: The 3Cs program is an educational strategy aimed at fostering resilience and compassion in people. It is based on improving the mental well-being of the participants by transforming their attitudes and behaviors through increased consciousness.
Study NCT03939585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellular therapy product
Description: Cellular therapy product: Allogeneic transplant donor lymphocytes, depleted of TCR-αβ T cells and B cells; enriched for NK cells and TCRγδ T cells.~* Infused using venous catheter on post-transplant Day 28 (+ 7 days).~* Single infusion of entire lymphocyte product derived from two-blood volume leukapheresis (non-mobilized).
Study NCT05060432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC chemotherapies
Description: SOC chemotherapies in 1L mNSCLC
Study NCT05476614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga (Robot-instructed)
Description: Yoga that is instructed by a social robot
Study NCT06105866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tricuspid Annular Plane Systolic Excursion
Description: Transthoracic echocardiography will be performed on patients during hospitalization and preoperatively to investigate the relationship between preoperative fasting and right ventricular functions. This will be examined by looking at TAPSE
Study NCT05992415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Using Patient Navigators
Description: Consented participants referred to ophthalmology from the 9 developments randomized to the Intervention Arm will receive ongoing support from patient navigators to assist with all aspects of follow-up eye care, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.
Study NCT05992415 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care Without Patient Navigators
Description: Consented participants referred from the 5 developments randomized to the Usual Care Arm 2 who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence. Arm 2 represents a realistic choice available for participants following screening over a 1-year period.
Study NCT05476614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga (Human-instructed)
Description: Yoga that is instructed by a human
Study NCT04323020 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT Perfusion
Description: CT Perfusion
Study NCT06285149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icaritin
Description: This product is suitable for patients with unresectable hepatocellular carcinoma who are not suitable for or refuse to receive standard treatment and have not received systemic treatment in the past, and the peripheral blood compound markers of patients meet at least two of the following detection indicatorsItem: AFP>400 ng/mL; TNF-a\<2.5 pg/mL; IFN-y>7.0 pg/mL.The conditional approval is based on data from an interim analysis of an enriched population in a randomized controlled Phase 11 clinical trial, and full approval for this indication will be subject to confirmation of the clinical benefit of the product in planned confirmatory trials.
Study NCT06145867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy
Description: deep red light therapy (670nm)
Study NCT04966416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyrophosphate
Description: 50 mg/kg bwt once daily in gelatine capsules.
Study NCT06333223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixture of (Poly)phenols and a probiotic supplement
Description: Mixture of (Poly)phenols and a probiotic supplement
Study NCT06333223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Mixture of (Poly)phenols and a placebo maltodextrin comparator
Study NCT05992376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food system and demand generation
Description: The Vegetables for All program will create FitFood Zones (FFZs) in low-income estates in urban and peri-urban areas with a minimum of 1,000 households and 10 mama mbogas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will support mama mbogas to source vegetables from Good Agricultural Practices (GAP)-compliant suppliers, support the uptake of digital solutions for mama mbogas to access vegetables, create business-to-business mentorship opportunities, and support county governments to improve market infrastructure. To encourage BoP parents of children 3-11 years to buy and consume more vegetables, the program will include a demand generation component. This will be implemented through a communication campaign, including above-the-line (ATL) activities (mass media such as radio and television), below-the-line (BTL) activities (market activations and others), and FFZ branding.
Study NCT04966416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glucose in gelatine capsules.
Study NCT05937321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Share plus intervention
Description: Participants will receive the Share plus intervention:~* Set up Follow app~* Start Share plus intervention~* Communication and problem-solving strategies~* Detailed action plan including glucose targets~* Review communication and problems~* New communication content~* Revise action plan as needed for communication and problem-solving hypo- and hyperglycemia,~* Dyadic glucose pattern management training using Clarity, set automatic Clarity downloads~* Dyad set goals for regular times to discuss glucose trends and problem-solving~* Dyadic review of glucose targets after an in-depth analysis of CGM data and dyadic treatment strategies to improve glucose TIR
Study NCT05937321 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Diabetes self-management education materials
Study NCT05403736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Aggressive Risk MitigAtion Plan
Description: Cardio-oncology consultation along with long-term collaborative cancer care visits during standard of care radiation therapy that will occur weekly for up to 6 weeks followed by 6-week and 3-month follow-up visits. Health will be monitored with biosensor monitoring devices.
Study NCT06127914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Early Infant Feeding Cues
Description: The LEIFc intervention includes individualized responsive feeding education and promotion using the SS-OO-PP-RR (or super, Setting the Stage, Observation and Opportunities to Embed, Problem Solving and Planning, Reflection and Review coaching approach as a guide. An interventionists interacts with mother-infant dyads during a feeding session at infant ages of 1, 2, 3, 4, and 5 months and coaches the mother on responsive feeding. In particular infant cues of hunger and fullness and tips to assist the mother in making decisions regarding feeding her infant. This will begin with milk based feedings (either breastmilk from breast or bottle, or formula from a bottle), and continue through the transition to solid (complementary) foods.
Study NCT06486181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrombolysis/Thrombectomy
Description: Endovascular interventions will be either catheter directed thrombolysis or mechanical thrombectomy procedures both of which have been cleared by FDA for the treatment of acute DVT.~Catheter-directed thrombolysis involves the use of a catheter to deliver thrombolytic agents directly to the site of the clot, effectively dissolving the thrombus. Mechanical thrombectomy, on the other hand, employs specialized devices to physically remove the clot from the vessel. These procedures have been cleared by FDA as they are targeted approaches to safely and effectively restore blood flow and reduce the risk of complications associated with acute DVT.
Study NCT05692999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q6W
Description: Pembrolizumab 200mg Q6W
Study NCT05692999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed 500 mg/m^2 Q3W
Description: Pemetrexed 500 mg/m\^2 Q3W
Study NCT05692999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m^2 Q3W
Description: Pemetrexed 500 mg/m\^2 Q3W
Study NCT05692999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab 200 mg Q3W or 400 mg Q6W
Description: Pembrolizumab 200 mg Q3W or 400 mg Q6W
Study NCT05298020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 400mg,sc,d1,Q4W
Study NCT05298020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 210mg，CIV72h，d1-3，Q4W
Study NCT05298020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125mg/m2,iv,d1,d8,Q4W
Study NCT05298020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2, iv,d1,d8，Q4W
Study NCT06552429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α-2b injection
Description: Peginterferon α-2b injection, 135 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
Study NCT06552429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α-2b injection
Description: Peginterferon α-2b injection, 180 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
Study NCT05162586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran low dose
Description: Participants will receive film-coated tablets of Enpatoran at a low dose orally, twice daily (BID) up to 24 weeks.
Study NCT05162586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran medium dose
Description: Participants will receive film-coated tablets of Enpatoran at a medium dose, orally, BID up to 24 weeks.
Study NCT05162586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran high dose
Description: Participants will receive film-coated tablets of Enpatoran at a high dose, orally, BID up to 24 weeks.
Study NCT05162586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to Enpatoran up to 24 weeks.
Study NCT05851677 — intervention group
Intervention type: DRUG
Intervention: Disitamab vedotin
Description: recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
Study NCT06557759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening to Calming Music
Description: Participants will listen to calming music, which may enhance health and wellness by reducing autonomic reactivity and improving bodily awareness, brain-body connection, and emotional wellbeing.
Study NCT05489887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naxitamab
Description: Naxitamab is a humanized (IgG1) anti-GD2 (hu3F8) monoclonal antibody for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was granted accelerated approval by the FDA in 2020 as treatment (in combination with granulocyte-macrophage colony-stimulating factor - GM-CSF) for pediatric patients at least one year of age and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy
Study NCT05489887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Ceritinib is an inhibitor that selectively targets the ALK tyrosine kinase
Study NCT06412445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair applying tissue glue for mesh fixation
Description: The operation will be performed using 3 trocars, with 10 mm trocar above the umbilicus and 5 mm and 12 mm trocars at the level of the umbilicus in the left and right midclavicular lines. Pneumoperitoneum will be established and a 30° optic will be used. After accessing the inguinal region, dissection of the parietal peritoneum will be performed in the direction from the anterior superior iliac spine up to the medial umbilical ligament. During dissection, gonadal vessels, vas deferens, Cooper's ligament and the posterior fascia of the rectus abdominis muscle will be visualized and prepared. Then, the prepared implant sized 15×15 cm will be introduced, spread out in the abdominal cavity and placed in the groin in order to cover the hernia opening by 2-3 cm in all directions. Fixation will be based on a mechanical effect involving applying tissue glue for mesh fixation. Reconstruction of the parietal peritoneum will be followed, with continuous absorbable sutures.